Figure 3 and Figure 4 demonstrate that L-NAME-treated rats showed significantly increased gene expression of AT1R, TGF-β, Col I, and GPx. In the Los-exposed group, the expression of AT1R, TGF-β, and NOX4 decreased, even though the expression of most antioxidant enzymes remained unchanged, indicating that in our condition AT1R, TGF-β, and NOX4 might be therapeutic targets for Los in the treatment of hypertension. Interestingly, the PGBR-treated group significantly suppressed AT1R and TGF-β expression at the same level as the control and Los-treated groups (Figure 3). This evidence concerns the gene NOX4 and hypertensive disorder.